Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Anthony J. Iafrarte"'
Autor:
Timothy M. Kuzel, Gary I. Cohen, Ahmad A. Tarhini, Christopher D. Lao, Sandra J. Lee, Darell R. Borger, Andrew L. Pecora, Henry B. Koon, John M. Kirkwood, Krista M. Rubin, Mario M. Leitao, Kim Margolin, Kevin Kalinsky, Anthony J. Jaslowski, Anthony J. Iafrarte, Donald P. Lawrence
Publikováno v:
Cancer. 123:2688-2697
BACKGROUND KIT-directed tyrosine kinase inhibitors such as imatinib have demonstrated benefits in KIT-mutant (KIT+) mucosal, acral, vulvovaginal, and chronically sun-damaged (CSD) melanoma. Dasatinib has superior preclinical activity in comparison wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f597e1c0ed88b4d331927f46af85ea8e
https://doi.org/10.1002/cncr.30663
https://doi.org/10.1002/cncr.30663
Autor:
Kevin, Kalinsky, Sandra, Lee, Krista M, Rubin, Donald P, Lawrence, Anthony J, Iafrarte, Darell R, Borger, Kim A, Margolin, Mario M, Leitao, Ahmad A, Tarhini, Henry B, Koon, Andrew L, Pecora, Anthony J, Jaslowski, Gary I, Cohen, Timothy M, Kuzel, Christopher D, Lao, John M, Kirkwood
Publikováno v:
Cancer. 123(14)
KIT-directed tyrosine kinase inhibitors such as imatinib have demonstrated benefits in KIT-mutant (KIT+) mucosal, acral, vulvovaginal, and chronically sun-damaged (CSD) melanoma. Dasatinib has superior preclinical activity in comparison with other ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::293db0c531584e69264ceca89aa6dca6
https://pubmed.ncbi.nlm.nih.gov/28334439
https://pubmed.ncbi.nlm.nih.gov/28334439